Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGF-Receptor 2 in patients with stage IV and locally advanced pancreatic cancer

BACKGROUND: The investigational oral DNA vaccine VXM01 targets the vascular endothelial growth factor receptor 2 (VEGFR-2) and uses Salmonella typhi Ty21a as a vector. The immune reaction elicited by VXM01 is expected to disrupt the tumor neovasculature and, consequently, inhibit tumor growth. VXM01...

Descripción completa

Detalles Bibliográficos
Autores principales: Niethammer, Andreas G, Lubenau, Heinz, Mikus, Gerd, Knebel, Philipp, Hohmann, Nicolas, Leowardi, Christine, Beckhove, Philipp, Akhisaroglu, Mustafa, Ge, Yingzi, Springer, Marco, Grenacher, Lars, Buchler, Markus W, Koch, Moritz, Weitz, Jürgen, Haefeli, Walter E, Schmitz-Winnenthal, Friedrich H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3493262/
https://www.ncbi.nlm.nih.gov/pubmed/22906006
http://dx.doi.org/10.1186/1471-2407-12-361

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3493262/
https://www.ncbi.nlm.nih.gov/pubmed/22906006
http://dx.doi.org/10.1186/1471-2407-12-361

Ejemplares similares